AstraZeneca’s (LSE:AZN) rare disease division, Alexion, has received a regulatory boost after the U.S. Food and Drug Administration accepted and granted priority review to a supplemental biologics ...
AstraZeneca's Ultomiris granted Priority Review by US FDA for adults with IgAN: Cambridge, UK Tuesday, June 16, 2026, 13:00 Hrs [IST] AstraZeneca has announced that Alexion, Astra ...
Recently published Nephrotic Syndrome Market Insights report includes a comprehensive understanding of current treatment practices, nephrotic syndrome emerging drugs, market share of individual ...
AstraZeneca announces positive results from MULBERRY phase III trial of efzimfotase alfa, an investigational enzyme replacement therapy: Cambridge, UK Tuesday, June 30, 2026, 11:0 ...
The class of drugs known as DNA Damage Response inhibitors, which work by blocking cancer cells’ ability to repair their own damaged DNA, is expanding rapidly beyond its original anchor, the PARP ...
(Alliance News) - AstraZeneca PLC on Monday said the US Food & Drug Administration has accepted and granted priority review to a supplemental biologics licence application for Ultomiris as a treatment ...
Restart your Windows PC and then try using the MSINFO32.exe tool. This will kill all extra processes and reset any corrupt files or temporary settings that may be preventing the tool from running ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results